Nonetheless, the use of liposomal formulations to vehicle a potent, but not cell-permeable, PIN1 inhibitor in cancer cells has shown effectiveness in curbing tumor growth in vivo (175), implying that such a strategy could be applied to other inhibitors with scarce pharmacokinetic properties. The gene discussed is PIN1; the disease is cancer.